2 weeks Ago Bet_Noire Relmada Therapeutics ( NASDAQ: RLMD ) shares finished Monday’s session 5% higher after the company reported it would no longer pursue two Phase 3 studies for its drug REL-1017 and was exploring strategic options. The drug developer said that after evaluating the full.
